Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab versus ranibizumab for myopic choroidal neovascularization
2023-506707-25-00Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of faricimab in myopic choroidal neovascularisation (mCNV) (2 arms), sponsored by Roche. Primary endpoint: Change from baseline in BCVA averaged over Weeks 4, 8, and 12. Started Mar 2024; status: completed.
02
Drugs
faricimab
03
Conditions
myopic choroidal neovascularisation (mCNV)
Beyond the preview
Go deeper on 2023-506707-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506707-25-00.